The phenotype of congenital insensitivity to pain due to the NaV1.9 variant p.L811P.

Abstract

Individuals with congenital insensitivity to pain (CIP) have never felt pain despite possessing an anatomically normal peripheral nervous system and normal intelligence.1 In 2006/7, biallelic null mutations in the transmembrane voltage-gated sodium channel NaV1.7/SCN9A were discovered as a cause of CIP.2, 3 Recently, a new form of CIP was reported in two isolated unrelated cases. Both had recurrent injuries and self-mutilations secondary to feeling no pain, and identical de novo heterozygous p.L811P variants in the voltage-gated sodium channel NaV1.9, encoded by SCN11A.4 We have now identified a further case with the identical variant c.2432T>C (p.(L811P)) and report that all have a complex extended phenotype, see Table 1. Table 1 A comparison of the phenotype of each individual with congenital insensitivity to pain due to SCN11A/NaV1.9 variant p.L811P The presenting feature in all three was failure to thrive secondary to intestinal dysmotility. Consequent upon this, all had multiple hospital admissions and investigations and two required parenteral nutrition. Abnormal gut peristalsis was found; however, intestinal biopsies were repeatedly normal. All have continuing problems with diarrhoea and/or constipation. All three have severe pruritus, scratching themselves sufficiently to cause full-thickness skin loss in the cervical area during infancy (see Figure 1). Remarkably this was at the same location as seen in transgenic Scn11a-mutant mice.4 Ulceration and itching may be secondary to hyperhidrosis, as itching only reduced following the use of cyprohepatidine, which lead to a clear reduction in sweating. Hyperhidrosis persisted throughout life, and increased on exertion and raised ambient temperatures. All cried and blushed normally, and none had any abnormal cardiovascular findings nor emotional liability. Figure 1 Neck of case 3 with the SCN11A/NaV1.9 mutation p.L811P at the age of 1 year 5 months. A large contiguous healing region is shown. This was caused by the child scratching, mostly while awake. This area was excoriated for 6 months due to intense itching ... Motor milestones were delayed, consequences of a persisting hypotonia and mild muscle weakness. No clinical or significant neurophysiological signs of peripheral neuropathy were observed. Two individuals adopted bizarre dystonia-like postures at the extremes of normal joint positions, awake and asleep. All have slow wound healing, and patient 3 in particular had Staphylococci repeatedly cultured from skin lesions. This apparent selective reduced immunity to staphylococcal infections is also seen in the hereditary autonomic and sensory neuropathy types 4 and 5, caused by biallelic mutations in NTRK1 and NGF, respectively. No peripheral pain was felt, for example, painless bone fractures and self-amputation of the tongue tip and lips, however, defecation produced significant discomfort. Furthermore, whereas temperature within the normal range could be perceived, variations in temperature such as a gust of cold wind were distinctly unpleasant. These were the only experiences of ‘pain' that the individuals describe. NaV1.9 is strongly expressed in enteric plexus and nociceptor/temperature sensing neurons, which patient biopsies show are present. Therefore the phenotype is mainly caused by nerve dysfunction and not by its absence. The p.L811P variant causes a complex pattern of effects on neuronal subtype activity: it is excitatory in the enteric plexus (NaV1.9 knockout mice have increased intestinal activity5), in sweat glands leading to hyperhidrosis and in ano-rectal nociceptors showing these innervations are functioning; but it is inhibitory in most nociceptors and in infective inflammation (which also occur in sensory neuropathies where small unmyelinated nerves are absent). The NaV1.9–CIP phenotype is unique and clearly clinically distinguishable from NaV1.7–CIP, which is accompanied by anosmia but not gastrointestinal motility disturbances or muscle weakness. In contrast to these channelopathies, the NTRK1-associated hereditary autonomic and sensory neuropathy type 4 (also termed ‘congenital insensitivity to pain with anhidrosis') is characterized by variable degree of intellectual disability and lack of sweat gland innervation, resulting in anhidrosis and recurrent febrile episodes owing to poor thermoregulation. The complex pathophysiological basis of the NaV1.9–CIP is further illustrated by the report of families with a dominant episodic pain syndrome caused by missense SCN11A/NaV1.9 variants and by further missense variants leading to adult onset painful neuropathy.6, 7 All mutations including p.L811P show gain-of-function properties at a channel level and suggest neuron hyperexcitability.4, 6, 7 Yet the contrary physiological outcome depending on the variant, that is, increased versus abolished pain perception, remains puzzling. One explanation might be the effect size of the respective mutation on NaV1.9 function that determines the physiological consequences. This recent insight in human NaV1.9 pathology suggests that channel agonists and antagonists could have multiple therapeutic potentials. Information regarding the SCN11A variant c.2432T>C (p.Leu811Pro) ({type:entrez-nucleotide,attrs:{text:NM_014139.2,term_id:115583666,term_text:NM_014139.2}}NM_014139.2) is available: OMIM Mutation ID 604385.0001 http://omim.org/entry/604385#0001; ClinVar: http://www.ncbi.nlm.nih.gov/clinvar/RC74494/ Patient consent had been obtained.